Monopar Therapeutics (MNPR)
(Delayed Data from NSDQ)
$4.54 USD
+0.04 (0.89%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $4.37 -0.17 (-3.74%) 7:58 PM ET
4-Sell of 5 4
F Value C Growth D Momentum F VGM
Monopar Therapeutics Inc. (MNPR) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$10.50 | $15.00 | $6.00 | 133.33% |
Price Target
Based on short-term price targets offered by two analysts, the average price target for Monopar Therapeutics Inc. comes to $10.50. The forecasts range from a low of $6.00 to a high of $15.00. The average price target represents an increase of 133.33% from the last closing price of $4.50.
Analyst Price Targets (2 )
Broker Rating
Monopar Therapeutics Inc. currently has an average brokerage recommendation (ABR) of 1.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by two brokerage firms. The current ABR compares to an ABR of 1.00 a month ago based on two recommendations.
Of the two recommendations deriving the current ABR, two are Strong Buy, representing 100% of all recommendations. A month ago, Strong Buy represented 100%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 2 | 2 | 2 | 2 | 2 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
8/14/2024 | H.C. Wainwright & Co. | Sean Lee | Strong Buy | Strong Buy |
8/13/2024 | Brookline Capital Markets | Kemp Dolliver | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.00 |
ABR (Last week) | 1.00 |
# of Recs in ABR | 2 |
Average Target Price | $10.50 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 85 of 253 |
Current Quarter EPS Est: | -0.46 |
MNPR FAQs
Monopar Therapeutics Inc. (MNPR) currently has an average brokerage recommendation (ABR) of 1.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 2 brokerage firms.
The average price target for Monopar Therapeutics Inc. (MNPR) is $10.50. The current on short-term price targets is based on 2 reports.
The forecasts for Monopar Therapeutics Inc. (MNPR) range from a low of $6 to a high of $15. The average price target represents a increase of $131.28 from the last closing price of $4.54.
The current UPSIDE for Monopar Therapeutics Inc. (MNPR) is 131.28%
Based on short-term price targets offered by two analysts, the average price target for Monopar Therapeutics Inc. comes to $10.50. The forecasts range from a low of $6.00 to a high of $15.00. The average price target represents an increase of 133.33% from the last closing price of $4.50.